194 related articles for article (PubMed ID: 17461989)
1. The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition.
Kino T; Rice KC; Chrousos GP
Eur J Clin Invest; 2007 May; 37(5):425-33. PubMed ID: 17461989
[TBL] [Abstract][Full Text] [Related]
2. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Serrano-Marco L; Barroso E; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
Diabetologia; 2012 Mar; 55(3):743-51. PubMed ID: 22179221
[TBL] [Abstract][Full Text] [Related]
3. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
Coll T; Alvarez-Guardia D; Barroso E; Gómez-Foix AM; Palomer X; Laguna JC; Vázquez-Carrera M
Endocrinology; 2010 Apr; 151(4):1560-9. PubMed ID: 20185762
[TBL] [Abstract][Full Text] [Related]
5. 3-O-Formyl-20R,21-epoxyresibufogenin suppresses IL-6-type cytokine actions by targeting the glycoprotein 130 subunit: potential clinical implications.
Kino T; Boos TL; Sulima A; Siegel EM; Gold PW; Rice KC; Chrousos GP
J Allergy Clin Immunol; 2007 Aug; 120(2):437-44. PubMed ID: 17451794
[TBL] [Abstract][Full Text] [Related]
6. Activation of PPARδ attenuates neurotoxicity by inhibiting lipopolysaccharide-triggered glutamate release in BV-2 microglial cells.
Lee WJ; Ham SA; Yoo H; Hwang JS; Yoo T; Paek KS; Lim DS; Han SG; Lee CH; Hong K; Seo HG
J Cell Biochem; 2018 Jul; 119(7):5609-5619. PubMed ID: 29388693
[TBL] [Abstract][Full Text] [Related]
7. Ligand-Activated Peroxisome Proliferator-Activated Receptor δ Attenuates Vascular Oxidative Stress by Inhibiting Thrombospondin-1 Expression.
Ahn MY; Ham SA; Yoo T; Lee WJ; Hwang JS; Paek KS; Lim DS; Han SG; Lee CH; Seo HG
J Vasc Res; 2018; 55(2):75-86. PubMed ID: 29408825
[TBL] [Abstract][Full Text] [Related]
8. The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.
Barroso E; Eyre E; Palomer X; Vázquez-Carrera M
Biochem Pharmacol; 2011 Feb; 81(4):534-43. PubMed ID: 21146504
[TBL] [Abstract][Full Text] [Related]
9. PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells.
Thulin P; Glinghammar B; Skogsberg J; Lundell K; Ehrenborg E
Int J Mol Med; 2008 Jun; 21(6):819-24. PubMed ID: 18506377
[TBL] [Abstract][Full Text] [Related]
10. Bioactivity screening and mass spectrometric confirmation for the detection of PPARδ agonists that increase type 1 muscle fibres.
Bovee TF; Blokland M; Kersten S; Hamers AR; Heskamp HH; Essers ML; Nielen MW; van Ginkel LA
Anal Bioanal Chem; 2014 Jan; 406(3):705-13. PubMed ID: 24287635
[TBL] [Abstract][Full Text] [Related]
11. Effects of peroxisome proliferator-activated receptor-β/δ on sepsis induced acute lung injury.
Wang C; Zhou G; Zeng Z
Chin Med J (Engl); 2014; 127(11):2129-37. PubMed ID: 24890166
[TBL] [Abstract][Full Text] [Related]
12. Activation of peroxisome proliferator-activated receptor delta suppresses BACE1 expression by up-regulating SOCS1 in a JAK2/STAT1-dependent manner.
Lee WJ; Ham SA; Lee GH; Choi MJ; Yoo H; Paek KS; Lim DS; Hong K; Hwang JS; Seo HG
J Neurochem; 2019 Nov; 151(3):370-385. PubMed ID: 31063584
[TBL] [Abstract][Full Text] [Related]
13. PPARδ agonist enhances colitis-associated colorectal cancer.
Zhou D; Jin J; Liu Q; Shi J; Hou Y
Eur J Pharmacol; 2019 Jan; 842():248-254. PubMed ID: 30391747
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI
Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis.
Pesant M; Sueur S; Dutartre P; Tallandier M; Grimaldi PA; Rochette L; Connat JL
Cardiovasc Res; 2006 Feb; 69(2):440-9. PubMed ID: 16337160
[TBL] [Abstract][Full Text] [Related]
16. Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model.
Li X; Li J; Lu X; Ma H; Shi H; Li H; Xie D; Dong L; Liang C
Int J Mol Med; 2015 Sep; 36(3):767-75. PubMed ID: 26133486
[TBL] [Abstract][Full Text] [Related]
17. Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.
Serrano-Marco L; Rodríguez-Calvo R; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
Diabetes; 2011 Jul; 60(7):1990-9. PubMed ID: 21617181
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta.
Kim HJ; Ham SA; Kim SU; Hwang JY; Kim JH; Chang KC; Yabe-Nishimura C; Kim JH; Seo HG
Circ Res; 2008 Feb; 102(2):193-200. PubMed ID: 18007025
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor-delta upregulates 14-3-3 epsilon in human endothelial cells via CCAAT/enhancer binding protein-beta.
Brunelli L; Cieslik KA; Alcorn JL; Vatta M; Baldini A
Circ Res; 2007 Mar; 100(5):e59-71. PubMed ID: 17303761
[TBL] [Abstract][Full Text] [Related]
20. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW501516 on bone and muscle in ovariectomized rats.
Mosti MP; Stunes AK; Ericsson M; Pullisaar H; Reseland JE; Shabestari M; Eriksen EF; Syversen U
Endocrinology; 2014 Jun; 155(6):2178-89. PubMed ID: 24708238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
